Jafargholi Rangraz Esmaeel, Tang Xikai, Van Laeken Charlotte, Maleux Geert, Dekervel Jeroen, Van Cutsem Eric, Verslype Chris, Baete Kristof, Nuyts Johan, Deroose Christophe M
Nuclear Medicine, University Hospitals Leuven, Nuclear Medicine and Molecular Imaging, Department of Imaging & Pathology, Leuven, Belgium.
Digestive Oncology, University Hospitals Leuven, Leuven, Belgium.
EJNMMI Res. 2020 Aug 14;10(1):94. doi: 10.1186/s13550-020-00675-5.
Selective internal radiation therapy (SIRT) is a promising treatment for unresectable hepatic malignancies. Predictive dose calculation based on a simulation using Tc-labeled macro-aggregated albumin (Tc-MAA) before the treatment is considered as a potential tool for patient-specific treatment planning. Post-treatment dose measurement is mainly performed to confirm the planned absorbed dose to the tumor and non-tumor liver volumes. This study compared the predicted and measured absorbed dose distributions.
Thirty-one patients (67 tumors) treated by SIRT with resin microspheres were analyzed. Predicted and delivered absorbed dose was calculated using Tc-MAA-SPECT and Y-TOF-PET imaging. The voxel-level dose distribution was derived using the local deposition model. Liver perfusion territories and tumors have been delineated on contrast-enhanced CBCT images, which have been acquired during the Tc-MAA work-up. Several dose-volume histogram (DVH) parameters together with the mean dose for liver perfusion territories and non-tumoral and tumoral compartments were evaluated.
A strong correlation between the predicted and measured mean dose for non-tumoral volume was observed (r = 0.937). The ratio of measured and predicted mean dose to this volume has a first, second, and third interquartile range of 0.83, 1.05, and 1.25. The difference between the measured and predicted mean dose did not exceed 11 Gy. The correlation between predicted and measured mean dose to the tumor was moderate (r = 0.623) with a mean difference of - 9.3 Gy. The ratio of measured and predicted tumor mean dose had a median of 1.01 with the first and third interquartile ranges of 0.58 and 1.59, respectively. Our results suggest that Tc-MAA-based dosimetry could predict under or over dosing of the non-tumoral liver parenchyma for almost all cases. For more than two thirds of the tumors, a predictive absorbed dose correctly indicated either good tumor dose coverage or under-dosing of the tumor.
Our results highlight the predictive value of Tc-MAA-based dose estimation to predict non-tumor liver irradiation, which can be applied to prescribe an optimized activity aiming at avoiding liver toxicity. Compared to non-tumoral tissue, a poorer agreement between predicted and measured absorbed dose is observed for tumors.
选择性体内放射治疗(SIRT)是一种有前景的不可切除性肝恶性肿瘤治疗方法。基于治疗前使用锝标记的大颗粒白蛋白(Tc-MAA)进行模拟的预测剂量计算被视为患者特异性治疗计划的潜在工具。治疗后剂量测量主要用于确认肿瘤和非肿瘤肝脏体积的计划吸收剂量。本研究比较了预测和测量的吸收剂量分布。
分析了31例接受树脂微球SIRT治疗的患者(67个肿瘤)。使用Tc-MAA-SPECT和Y-TOF-PET成像计算预测和实际给予的吸收剂量。使用局部沉积模型得出体素级剂量分布。在Tc-MAA检查期间采集的对比增强CBCT图像上勾勒出肝脏灌注区域和肿瘤。评估了几个剂量体积直方图(DVH)参数以及肝脏灌注区域、非肿瘤和肿瘤区域的平均剂量。
观察到非肿瘤体积的预测平均剂量与测量平均剂量之间存在强相关性(r = 0.937)。该体积的测量平均剂量与预测平均剂量之比的第一、第二和第三四分位数范围分别为0.83、1.05和1.25。测量平均剂量与预测平均剂量之间的差异不超过11 Gy。肿瘤的预测平均剂量与测量平均剂量之间的相关性为中等(r = 0.623),平均差异为 - 9.3 Gy。测量肿瘤平均剂量与预测肿瘤平均剂量之比的中位数为1.01,第一和第三四分位数范围分别为0.58和1.59。我们的结果表明,基于Tc-MAA的剂量测定法几乎可以在所有情况下预测非肿瘤肝实质的剂量不足或过量。对于超过三分之二的肿瘤,预测吸收剂量正确地表明了良好的肿瘤剂量覆盖或肿瘤剂量不足。
我们的结果突出了基于Tc-MAA的剂量估计对预测非肿瘤肝脏照射的预测价值,可用于规定优化活度以避免肝毒性。与非肿瘤组织相比,肿瘤的预测吸收剂量与测量吸收剂量之间的一致性较差。